Mon. 3 Jun 2024, 4:40am ET
Benzinga
News
- KT-253 demonstrates initial clinical proof of concept in patients with tumor types shown to be sensitive in preclinical models, including responses in MCC and AML
- Evidence of target engagement and potent upregulation of p53 pathway biomarkers even at the lowest dose levels in solid tumor and AML patients
- KT-253 was generally well tolerated without hematologic adverse events seen with traditional MDM2 small molecule inhibitors
- KT-253 Phase 1 study ongoing with additional data expected in the second half of 2024